
glenmark
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Topics
Glenmark Pharmaceuticals | USFDA

glenmark
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Glenmark Pharmaceuticals on Thursday said it has received an approval from the US health regulator to market a generic medication to treat plaque psoriasis.
The company has received final approval from the US Food & Drug Administration (USFDA) for Calcipotriene and Betamethasone Dipropionate Foam, the generic version of Leo Pharma's Enstilar, Glenmark Pharma said in a statement.
The USFDA noted that the Mumbai-based drug firm was the first abbreviated new drug application (ANDA) applicant with a paragraph IV certification for Calcipotriene and Betamethasone Dipropionate Foam, it added.
"Therefore, with this approval, Glenmark is eligible for 180 days of generic drug exclusivity for Calcipotriene and Betamethasone Dipropionate Foam," the drug firm said.
According to IQVIA sales data for the 12-month period ended January 2023, Enstilar Foam (0.005 per cent/0.064 per cent) achieved annual sales of around USD 93.6 million.
Shares of the company were trading 0.49 per cent down at Rs 434.20 apiece on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Thu, March 23 2023. 12:29 IST
Coutts steps into private marketsCoutts, the private bank best known for serving Britain’s wealthiest families and the... Read more
How Crypto Moved from the Wild West to the Mainstream Financial SystemA long-form analysis of Bitcoin's journey from fri... Read more
ACB Securities: Building Scale, Trust and Innovation in Vietnam’s Capital MarketsACB Securities (ACBS) is emerging as ... Read more
For most of the past year, global markets behaved as though geopolitical risk had largely disappeared. Inflation was eas... Read more
The payments system is undergoing a quiet but consequential shift. What was once the exclusive preserve of central banks... Read more
The Bank of England has taken a significant step towards easing post-crisis regulation by lowering its estimate of the c... Read more